AR044507A1 - Compuestos de quinolina y quinoxalina - Google Patents
Compuestos de quinolina y quinoxalinaInfo
- Publication number
- AR044507A1 AR044507A1 ARP040101024A ARP040101024A AR044507A1 AR 044507 A1 AR044507 A1 AR 044507A1 AR P040101024 A ARP040101024 A AR P040101024A AR P040101024 A ARP040101024 A AR P040101024A AR 044507 A1 AR044507 A1 AR 044507A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- carbon
- optionally
- nitrogen
- optionally mono
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos de quinolina y quinoxalina, composiciones farmacéuticas que contienen tales compuestos y el uso de tales compuestos para aumentar ciertos niveles de lípidos en el plasma, incluyendo la lipoproteína de alta densidad del colesterol y para reducir otros niveles de lípidos en el plasma, tales como colesterol LDL y triglicéridos, y por consiguiente, para tratar enfermedades que se ven afectadas por los niveles bajos de colesterol HDL y/o niveles altos de colesterol LDL y triglicéridos, tales como ateroesclerosis y enfermedades cardiovasculares Reivindicación 1: Un compuesto de acuerdo con la fórmula (1) donde C3 es carbono; J es nitrógeno o carbono, donde si J es carbono, entonces el enlace entre C3 y J es un enlace sencillo o doble y si J es nitrógeno, entonces el enlace entre C3 y J es un enlace sencillo; R1 es Y, W-X o W-Y1; donde W es un carbonilo, tiocarbonilo, sulfinilo o sulfonilo; X es -O-Y, -S-Y, -N(H)-Y o -N-(Y)2; Y para cada caso es independientemente Z o una cadena carbonada totalmente saturada, parcialmente insaturada o totalmente insaturada de uno a diez miembros, lineal o ramificada donde cada carbono, distinto del carbono de unión, puede reemplazarse opcionalmente con uno o dos heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrógeno y donde dicho carbono está opcionalmente mono-, di- o tri-substituido independientemente con halo, estando dicho carbono opcionalmente mono-substituido con hidroxi, estando dicho carbono opcionalmente substituido con oxo, estando dicho azufre opcionalmente mono- o di-substituido con oxo, estando dicho nitrógeno opcionalmente mono-, o di-substituido con oxo, y estando dicha cadena carbonada opcionalmente mono-substituida con Z; e Y1 para cada caso es independientemente Z o una cadena carbonada totalmente saturada, parcialmente insaturada o totalmente insaturada de uno a diez miembros, lineal o ramificada, donde cada carbono, distinto del carbono de unión, puede reemplazarse opcionalmente con uno o dos heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrógeno y donde dicho carbono está opcionalmente mono-, di- o tri-substituido independientemente con halo, estando dicho carbono opcionalmente mono-substituido con hidroxi, estando dicho carbono opcionalmente mono-substituido con oxo, estando dicho azufre opcionalmente mono- o di-substituido con oxo, estando dicho nitrógeno opcionalmente mono-, o di-substituido con oxo, y estando dicha cadena carbonada opcionalmente mono-substituida con Z; donde Z es un anillo de tres a ocho miembros, parcialmente saturado, totalmente saturado o totalmente insaturado, que tiene opcionalmente de uno a cuatro heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrógeno, o un anillo bicíclico que consta de dos anillos condensados de tres a seis miembros, parcialmente saturados, totalmente saturados o totalmente insaturados, tomados independientemente, que tienen opcionalmente de uno a cuatro heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrógeno; y dicho substituyente Z está opcionalmente mono-, di- o tri-substituido independientemente con halo, alquenilo C2-6, alquilo C1-6, hidroxi, alcoxi C1-6, alquiltio C1-4, amino, nitro, ciano, oxo, carboxi, alquiloxicarbonilo C1-6, mono-N- o di-N,N-alquilamino C1-6 donde dicho substituyente alquilo C1-6 está opcionalmente mono-, di- o tri-substituido independientemente con halo, hidroxi, alcoxi C1-6, alquiltio C1-4, amino, nitro, ciano, oxo, carboxi, alquiloxicarbonilo C1-6, mono-N- o di-N,N-alquilamino C1-6, estando dicho substituyente alquilo C1-6 o alcoxi C1-6 opcionalmente substituido con uno a nueve átomos de flúor; R2 es una cadena carbonada, parcialmente saturada, totalmente saturada o totalmente insaturada de uno a seis miembros, lineal o ramificada, donde cada carbono, distinto del carbono de unión, puede reemplazarse opcionalmente con uno o dos heteroátomos seleccionados independientemente entre oxígeno y azufre, y donde dicho carbono está opcionalmente mono-, di- o tri-substituido independientemente con halo, estando dicha cadena carbonada opcionalmente mono-substituida con oxo, estando dicho carbono opcionalmente mono-substituido con hidroxi, estando dicho azufre opcionalmente mono- o di-substituido con oxo; o dicho R2 es un anillo parcialmente saturado, totalmente saturado o totalmente insaturado de tres a siete miembros, que tiene opcionalmente de uno a dos heteroátomos seleccionados independientemente entre oxígeno y azufre, donde dicho anillo R2 está opcionalmente unido mediante un alquilo C1-4; donde dicho anillo R2 está opcionalmente mono-, di- o tri-substituido independientemente con halo, alquenilo C2-6, alquilo C1-6, hidroxi, alcoxi C1-6, alquiltio C1-4, amino, nitro, ciano, oxo, carboxi, alquiloxicarbonilo, mono-N- o di-N,N-alquilamino C1-6 donde dicho substituyente alquilo C1-6 está opcionalmente mono- , di- o tri-substituido independientemente con halo, hidroxi, alcoxi C1-6, alquiltio C1-4, oxo o alquiloxicarbonilo C1-6; R3 es una cadena carbonada totalmente saturada, parcialmente insaturada o totalmente insaturada uno a seis miembros, lineal o ramificada, que contiene C4a, donde C4a es un átomo de carbono que conecta con J, donde cada carbono en la cadena carbonada puede reemplazarse opcionalmente con un heteroátomo seleccionado entre oxígeno, azufre y nitrógeno, y donde dicho carbono está opcionalmente mono-, di- o tri-substituido con halo, estando dicho carbono opcionalmente mono-substituido con hidroxi, estando dicho carbono opcionalmente mono-substituido con oxo o nitrógeno, estando dicho azufre opcionalmente mono- o di- substituido con oxo, estando dicho nitrógeno opcionalmente mono- o di-substituido con hidrógeno u oxo, y estando dicha cadena carbonada mono, di-, o tri-substituida con V en C4a o en el carbono R3 adyacente a C4a; siempre que en R3, cuando J es carbono, sea distinto de C4a que está opcionalmente reemplazado con un heteroátomo; y siempre que en R3, cuando J es nitrógeno, sea distinto de C4a que está opcionalmente reemplazado con un heteroátomo y sea distinto de C4a que está opcionalmente mono-substituido con hidroxi o nitrógeno; donde V es un anillo parcialmente saturado, totalmente saturado o totalmente insaturado de tres a ocho miembros, que tiene opcionalmente de uno a cuatro heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrógeno tal que V no es imidazolilo o un anillo heterocíclico totalmente saturado que contiene nitrógeno donde el nitrógeno del anillo está unido al grupo R3; un anillo bicíclico que consta de dos anillos condensados de tres a seis miembros, parcialmente saturados, totalmente saturados o totalmente insaturados, tomados independientemente, que tienen opcionalmente de uno a cuatro heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrógeno; o un anillo tricíclico que consiste de tres anillos condensados de tres a seis miembros, parcialmente saturados, totalmente saturados o totalmente insaturados, tomados independientemente, que tienen opcionalmente de uno a cuatro heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrógeno; y dicho substituyente V está opcionalmente mono-, di-, tri-, tetra- o penta-substituido independientemente con V1, alquil C1-6-V1, C(O)-V1, O-alquil C0-6-V1, alquil C1-6-O-V1, C(O)-mono-N- o di- N,N-alquil C1-6-V1, halo, alquilo C1-6, alquenilo C2-6, hidroxi, alcoxi C1-6, alquiltio C1-4, alquilsulfinilo C1-4, alquilsulfonilo C1-4, mono-N- o di-N,N-alquilsulfonilo C1-6, amino, nitro, ciano, oxo, carboxamoilo, mono-N- o di-N,N- alquilcarboxamoilo C1-6, carboxi, alquiloxicarbonilo C1-6, mono-N- o di-N,N-alquilamino C1-6, donde dicho substituyente alquilo C1-6 o alquenilo C2-6 está opcionalmente mono-, di- o tri-substituido independientemente con hidroxi, alcoxi C1-6, alquiltio C1-4, amino, nitro, ciano, oxo, carboxi, alquiloxicarbonilo C1-6, mono-N- o di-N,N-alquilamino C1-6, donde cada uno de los substituyentes alquilo C1-6, alcoxi C1-6, alquiltio C1-4, alquilsulfonilo C1-4 o alquenilo C2-6 también están opcionalmente substituidos con uno a nueve átomos de flúor; donde V1 es un anillo de tres a seis miembros, parcialmente saturado, totalmente saturado o totalmente insaturado, que tiene opcionalmente de uno a dos heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrógeno, o un anillo bicíclico que consta de dos anillos condensados de tres a seis miembros, parcialmente saturados, totalmente saturados o totalmente insaturados, tomados independientemente, que tienen opcionalmente de uno a cuatro heteroátomos seleccionados independientemente entre oxígeno, azufre y nitrógeno; y dicho substituyente V1 está opcionalmente mono-, di-, tri-, tetra- o penta-substituido independientemente con halo, alquilo C1-6, alcoxi C1-6, hidroxi, oxo, amino, nitro, ciano, alquiloxicarbonilo C1-6, mono-N- o di-N,N-alquilamino C1-6 donde dicho substituyente alquilo C1-6 está opcionalmente mono-substituido con oxo, dicho substituyente alquilo C1-6 o alcoxi C1-6 también están opcionalmente substituidos con uno a nueve átomos de flúor; y cada uno de R4, R5, R6 y R7 es independientemente hidrógeno, un enlace, nitro o halo donde dicho enlace está substituido con T o una cadena carbonada, parcialmente saturada, totalmente saturada o totalmente insaturada (C1-12), lineal o ramificada donde cada carbono puede reemplazarse opcionalmente con uno o dos heteroátomos por cadena carbonada donde los heteroátomos se seleccionan independientemente entre oxígeno, azufre y nitrógeno, donde dicho carbono está opcionalmente mono-, di- o tri-substituido independientemente con halo, estando dicho carbono opcionalmente mono-substituido con hidroxi, estando dicho carbono opcionalmente mono-substituido con oxo o nitrógeno, estando dicho azufre opcionalmente mono- o di-substituido con oxo, estando dicho nitrógeno opcionalmente mono- o di-substituido con hidrógeno u oxo, y estando dicha cadena
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45827403P | 2003-03-28 | 2003-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR044507A1 true AR044507A1 (es) | 2005-09-14 |
Family
ID=33098266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040101024A AR044507A1 (es) | 2003-03-28 | 2004-03-26 | Compuestos de quinolina y quinoxalina |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1622872A1 (es) |
JP (1) | JP2006521344A (es) |
KR (1) | KR100729883B1 (es) |
CN (1) | CN1795177A (es) |
AR (1) | AR044507A1 (es) |
AU (1) | AU2004224082A1 (es) |
BR (1) | BRPI0408897A (es) |
CA (1) | CA2520405A1 (es) |
CL (1) | CL2004000639A1 (es) |
EA (1) | EA200501376A1 (es) |
EC (1) | ECSP056040A (es) |
GT (1) | GT200400050A (es) |
HR (1) | HRP20050859A2 (es) |
MA (1) | MA27828A1 (es) |
MX (1) | MXPA05010456A (es) |
NL (1) | NL1025839C2 (es) |
NO (1) | NO20054989L (es) |
OA (1) | OA13153A (es) |
PA (1) | PA8598901A1 (es) |
PE (1) | PE20050389A1 (es) |
TN (1) | TNSN05243A1 (es) |
TW (1) | TWI285641B (es) |
UY (1) | UY28243A1 (es) |
WO (1) | WO2004085401A1 (es) |
ZA (1) | ZA200507819B (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GEP20084540B (en) | 2003-01-14 | 2008-11-25 | Arena Pharm Inc | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
ZA200508298B (en) | 2003-04-11 | 2007-01-31 | Ptc Therapeutics Inc | 1,2,4-oxadiazole benzoic acid compounds |
TWI335328B (en) | 2003-07-14 | 2011-01-01 | Arena Pharm Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto |
WO2006033001A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
US20070149567A1 (en) * | 2004-09-23 | 2007-06-28 | Pfizer Inc | Quinoline compounds |
AR051780A1 (es) * | 2004-11-29 | 2007-02-07 | Japan Tobacco Inc | Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos |
MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
MX2007010215A (es) * | 2005-02-24 | 2007-11-07 | Millennium Pharm Inc | Antagonistas del receptor pgd2 para el tratamiento de enfermedades inflamatorias. |
US7888376B2 (en) * | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
PE20071025A1 (es) * | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
US7745477B2 (en) * | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
UY30244A1 (es) | 2006-03-30 | 2007-11-30 | Tanabe Seiyaku Co | Un proceso para preparar derivados de tetrahidroquinolina |
US8232403B2 (en) | 2006-05-10 | 2012-07-31 | Novartis Ag | Bicyclic derivatives as CETP inhibitors |
JP4108729B2 (ja) * | 2006-05-26 | 2008-06-25 | 日本たばこ産業株式会社 | 窒素含有縮合環化合物含有医薬組成物 |
US20080305169A1 (en) * | 2006-05-26 | 2008-12-11 | Japan Tobacco Inc. | Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds |
KR20090078352A (ko) * | 2006-11-15 | 2009-07-17 | 노파르티스 아게 | 유기 화합물 |
JP4846769B2 (ja) * | 2007-07-30 | 2011-12-28 | 田辺三菱製薬株式会社 | 医薬組成物 |
WO2009029632A1 (en) | 2007-08-27 | 2009-03-05 | Helicon Therapeutics, Inc. | Therapeutic isoxazole compounds |
MX2011003951A (es) * | 2008-10-29 | 2011-05-03 | Hoffmann La Roche | Nuevos derivados de fenilamida o de piridilamida y su uso como agonistas de receptor acoplado a proteina g (gpbar1). |
US8420647B2 (en) | 2010-01-21 | 2013-04-16 | Hoffmann-La Roche Inc. | 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds |
CA2812061A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
CN106029076B (zh) | 2013-11-18 | 2019-06-07 | 福马疗法公司 | 作为bet溴域抑制剂的苯并哌嗪组合物 |
MX370535B (es) | 2013-11-18 | 2019-12-17 | Forma Therapeutics Inc | Compuestos de tetrahidroquinolina como inhibidores del bromodominio extra terminal y bromo (bet) y el uso de los mismos en el tratamiento de cáncer. |
TWI695717B (zh) | 2014-03-06 | 2020-06-11 | 美商 Ptc 治療公司 | 1,2,4-二唑苯甲酸之鹽及醫藥組合物 |
AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
KR102603199B1 (ko) | 2015-06-22 | 2023-11-16 | 아레나 파마슈티칼스, 인크. | S1p1 수용체-관련 장애에서의 사용을 위한 (r)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[b]인돌-3-일)아세트산 (화합물 1)의 결정성 l-아르기닌 염 |
JP2018531975A (ja) | 2015-10-30 | 2018-11-01 | ピーティーシー セラピューティクス,インコーポレーテッド | てんかんの治療方法 |
MX2019009841A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
CN110452183B (zh) * | 2019-09-04 | 2023-03-14 | 中国科学院上海有机化学研究所 | 一种手性杂环化合物的制备方法 |
CN111440162A (zh) * | 2020-04-01 | 2020-07-24 | 邱曲真 | 噻唑二氢萘类衍生物及其在代谢性疾病中的应用 |
CN114656406B (zh) * | 2022-01-25 | 2023-09-05 | 阿里生物新材料(常州)有限公司 | 一种2-氟代嘧啶-4-羧酸的合成方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE351464C (de) * | 1917-12-18 | 1922-04-07 | Chemische Werke Grenzach Aktie | Verfahren zur Darstellung von Derivaten einer hydrierten 2-Phenylchinolin-4-carbonsaeure |
DE69531998T2 (de) * | 1994-12-22 | 2004-07-22 | Ligand Pharmaceuticals, Inc., San Diego | Steroidrezeptor-modulator verbindungen und methoden |
CA2270123A1 (en) * | 1996-10-28 | 1998-05-07 | Department Of The Army, U.S. Government | Compounds, compositions and methods for treating antibiotic-resistant infections |
US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
DE69908555T2 (de) * | 1998-01-26 | 2004-05-06 | Smithkline Beecham P.L.C., Brentford | Chinolinderivate als antibakterielles arzneimittel |
GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
CO5271716A1 (es) * | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
-
2004
- 2004-03-15 KR KR1020057018383A patent/KR100729883B1/ko not_active IP Right Cessation
- 2004-03-15 MX MXPA05010456A patent/MXPA05010456A/es unknown
- 2004-03-15 BR BRPI0408897-2A patent/BRPI0408897A/pt not_active IP Right Cessation
- 2004-03-15 JP JP2006506369A patent/JP2006521344A/ja active Pending
- 2004-03-15 CN CNA2004800146455A patent/CN1795177A/zh active Pending
- 2004-03-15 CA CA002520405A patent/CA2520405A1/en not_active Abandoned
- 2004-03-15 EP EP04720668A patent/EP1622872A1/en not_active Withdrawn
- 2004-03-15 OA OA1200500269A patent/OA13153A/en unknown
- 2004-03-15 WO PCT/IB2004/000836 patent/WO2004085401A1/en active Application Filing
- 2004-03-15 EA EA200501376A patent/EA200501376A1/ru unknown
- 2004-03-15 AU AU2004224082A patent/AU2004224082A1/en not_active Abandoned
- 2004-03-23 GT GT200400050A patent/GT200400050A/es unknown
- 2004-03-25 UY UY28243A patent/UY28243A1/es not_active Application Discontinuation
- 2004-03-25 CL CL200400639A patent/CL2004000639A1/es unknown
- 2004-03-26 PA PA20048598901A patent/PA8598901A1/es unknown
- 2004-03-26 AR ARP040101024A patent/AR044507A1/es unknown
- 2004-03-26 PE PE2004000323A patent/PE20050389A1/es not_active Application Discontinuation
- 2004-03-26 NL NL1025839A patent/NL1025839C2/nl not_active IP Right Cessation
- 2004-03-26 TW TW093108314A patent/TWI285641B/zh not_active IP Right Cessation
-
2005
- 2005-09-26 EC EC2005006040A patent/ECSP056040A/es unknown
- 2005-09-27 ZA ZA200507819A patent/ZA200507819B/xx unknown
- 2005-09-28 TN TNP2005000243A patent/TNSN05243A1/fr unknown
- 2005-09-28 MA MA28519A patent/MA27828A1/fr unknown
- 2005-09-28 HR HR20050859A patent/HRP20050859A2/hr not_active Application Discontinuation
- 2005-10-26 NO NO20054989A patent/NO20054989L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MA27828A1 (fr) | 2006-04-03 |
CL2004000639A1 (es) | 2005-02-04 |
WO2004085401A1 (en) | 2004-10-07 |
AU2004224082A1 (en) | 2004-10-07 |
WO2004085401A8 (en) | 2005-12-01 |
KR20050115938A (ko) | 2005-12-08 |
PE20050389A1 (es) | 2005-05-30 |
NL1025839A1 (nl) | 2004-09-30 |
EP1622872A1 (en) | 2006-02-08 |
NO20054989L (no) | 2005-12-16 |
PA8598901A1 (es) | 2004-11-26 |
BRPI0408897A (pt) | 2006-04-18 |
NL1025839C2 (nl) | 2006-09-06 |
JP2006521344A (ja) | 2006-09-21 |
UY28243A1 (es) | 2004-11-08 |
GT200400050A (es) | 2005-03-02 |
OA13153A (en) | 2006-12-13 |
TNSN05243A1 (fr) | 2007-06-11 |
CN1795177A (zh) | 2006-06-28 |
NO20054989D0 (no) | 2005-10-26 |
HRP20050859A2 (en) | 2006-02-28 |
MXPA05010456A (es) | 2006-03-21 |
TW200508222A (en) | 2005-03-01 |
EA200501376A1 (ru) | 2006-04-28 |
CA2520405A1 (en) | 2004-10-07 |
KR100729883B1 (ko) | 2007-06-18 |
TWI285641B (en) | 2007-08-21 |
ECSP056040A (es) | 2006-01-27 |
ZA200507819B (en) | 2007-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR044507A1 (es) | Compuestos de quinolina y quinoxalina | |
AR030523A1 (es) | Compuestos 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-amino sustituidas, su uso en la preparacion de medicamentos, composiciones farmaceuticas, y equipo que los contiene. | |
CO5370678A1 (es) | 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas | |
AR087919A1 (es) | Heterociclos biciclicos como inhibidores de irak4 | |
AR086837A1 (es) | Moduladores heterociclicos de sintesis lipidica | |
CO6251209A2 (es) | Esteres ciclicos de boro y composiciones que los contienen | |
RS52397B (en) | PYRIDO / 2,1-A / ISOCHINOLINE DERIVATIVES AS DPP-IV INHIBITORS | |
MA37712A2 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
MX371337B (es) | Compuestos para protección de células. | |
AR106652A1 (es) | Compuestos para tratar la esclerosis lateral amiotrófica | |
AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
MX2012008049A (es) | Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,. | |
MX2010000658A (es) | Derivados de pirimidina 934. | |
RU2009148796A (ru) | Производные пиперидина/пиперазина | |
RS20080409A (en) | Dibenzyl amine derivatives as cetp inhibitors | |
AR072008A1 (es) | Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38 | |
AR066911A1 (es) | Derivados de piperidina / piperazina | |
IL181271A0 (en) | Triazolophthalazine derivatives and pharmaceutical compositions containing the same | |
PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
AR054481A1 (es) | Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol | |
AR054484A1 (es) | Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol | |
AR072578A1 (es) | Compuestos de piperidina puenteada tipo quinoxalina sustituida y los usos de los mismos | |
AR066154A1 (es) | Derivados de piperidina / piperazina | |
AR110443A1 (es) | Inhibidores de histona metiltransferasas | |
UY30787A1 (es) | "inhibidores benzoimidazolicos de trpv1" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |